Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Clinical treatment-failures to affordable drugs encouraged new investigation for discovery and development of new prophylactic and therapeutic interventions against malaria. The Drug Discovery Cluster (DDcl) of the Italian Malaria Network gathers several highly integrated and complementary laboratories from different Italian Institutions to identify, synthesise, screen in vitro and in vivo new antimalarial molecules directed against the intraerythrocytic stage of P. falciparum parasites and/or with transmission blocking activity to select lead compounds for further development. Complementary research activities, both in vitro and in the clinics, aim at investigating the pathogenetic mechanisms of severe malaria anaemia and the different manifestations of the disease in malaria-HIV co-infected patients to identify new therapies and improve survival.


Journal article



Publication Date





133 - 136


Dipartimento Salute Pubblica-Microbiologia-Virologia, Università di Milano, Italy.


Animals, Mice, Inbred BALB C, Humans, Mice, Anopheles, Plasmodium falciparum, Malaria, Falciparum, Kynurenine, Plant Extracts, Biological Products, Antimalarials, Insecticides, Drug Delivery Systems, Drug Evaluation, Preclinical, Parasitic Sensitivity Tests, Insect Vectors, Drug Design, Drug Resistance, Societies, Scientific, Italy